Craters Alzheimer’s

Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals

The biotech company said it will discontinue a second trial but will still offer a full analysis of the data.

Business - MarketWatch - Yesterday

Biogen’s stock hit by soft sales of Alzheimer’s treatment

“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company’s CEO said.

Business - MarketWatch - October 30

Chancellor and BoE governor call for UK to rebuild ties with EU

Reeves and Bailey highlight damage from Brexit amid concern about Trump’s plan to impose tariffs on trading partners

Business - Financial Times - November 14

Britain’s bold plan to create super funds

The case for consolidating the UK’s sprawling pension arsenal is strong

Business - Financial Times - November 14

Are cancer survivors less likely to develop Alzheimer’s?

Research shows that patients with a history of cancer are less likely to develop dementia and those with Alzheimer’s are less likely to develop cancer. Understanding this relationship, say ...

World - The Guardian - November 16

Cannabis stocks crater as Florida fails to garner needed votes for adult use

North Dakota and South Dakota also failed in their efforts to legalize cannabis for recreational use, while a medical measure passed in Nebraska.

Business - MarketWatch - November 6

Hearthstone's 2025 Roadmap Includes StarCraft Crossover, Return To Un'Goro Crater

Hearthstone's next mini-set is a StarCraft crossover: one that will reimagine the various units of Blizzard's beloved sci-fi RTS in card form. In addition to this, Blizzard announced an entire ...

Tech - GameSpot - November 13

Alzheimer's researchers say brain stimulation device may slow symptoms

Alzheimer's disease researchers found that when they aimed a TMS device at the right spot in the brain, it could slow the progression of memory loss.

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Business - The New York Times - Yesterday

‘A big cratering’: an expert on gen Z’s surprise votes – and young women’s growing support for Trump

The gender gap among young people was predictably vast. But the numbers still defied expectations, as the political scientist Melissa Deckman explains. A masculinity researcher on the Democrats’ ...

World - The Guardian - November 8

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.

Business - CNBC - October 30

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing ...

Business - MarketWatch - November 14

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Health - ABC News - November 14

‘We’re living in uncertainty’: My sister has Alzheimer’s disease. How do I know the right time to take control of her finances?

“My eldest sister has asked me to take on her power of attorney for her, and together we met with her attorney.”